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Abstract   
Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease. TGF-β1/Smad3 
signalling plays a major pathological role in DN; however, the contribution of Smad4 has not 
been examined. Knock-down of Smad4 expression in the kidney using an anti-Smad4 locked 
nucleic acid halted progressive podocyte damage and glomerulosclerosis in mouse type 2 DN, 
suggesting a pathogenic role of Smad4 in podocytes. We identified up-regulation of Smad4 in 
podocytes in human and mouse DN. Next, conditional Smad4 deletion in podocytes was 
shown to protected mice from type 2 DN independent of obesity. Mechanistically, 
hyperglycaemia induces Smad4 localisation to mitochondria in podocytes resulting in 
reduced glycolysis and oxidative phosphorylation, and increased production of reactive 
oxygen species. This operates, in part, via direct binding of Smad4 to the glycolytic enzyme 
PKM2 to reduce the active tetrameric form of PKM2. In addition, Smad4 interacts with 
ATPIF1, causing a reduction in ATPIF1 degradation. In conclusion, we have identified a 
novel mitochondrial-based mechanism by which Smad4 causes diabetic podocyte injury.  
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Introduction 
Type 2 diabetes is the most common cause of end-stage renal disease (ESRD) in developed 
countries. Current therapies rely upon treatment of hyperglycaemia and control of 
hypertension, focusing on inhibition of the renin-angiotensin-aldosterone system (RAAS) [1]. 
Despite attempts at optimal blood glucose and blood pressure control, diabetic nephropathy 
(DN) develops in many patients [2, 3], indicating that additional approaches are needed to 
halt the development and progression of DN. 
TGF-β1 regulates a diverse range of cellular responses [4], including proliferation, wound 
healing, differentiation, fibrosis, apoptosis and metabolism. Studies in human and 
experimental DN have identified a key role for TGF-β1 in the development and progression 
of DN [5]. However, systemic targeting of TGF-β1 carries significant risks as demonstrated 
by the severe organ inflammation and early lethality seen in mice lacking Tgfb1 [6], Tgfbr1 
[7], or lacking Tgfbr2 in T cells [8]. Therefore, approaches are need to target factors 
downstream of TGF-β1 and its receptor to suppress disease development. 
TGF-β1 exerts its major biological effects through its cell surface receptors; TGF-βRI and 
TGF-βRII [4]. Upon TGF-β1 binding, the TGF-βRI phosphorylates Smad2 and Smad3 which 
then oligomerize with Smad4 to form a complex that translocates into the nucleus. Smad3 
and/or Smad4 can directly bind to DNA sequences or cofactors to regulate transcription of 
their target genes [4]. Global deletion of Smad2 or Smad4 is lethal, whereas Smad3 deficient 
mice are viable [9], leading to a major focus on TGF-β1/Smad3 signalling. Mice lacking 
Smad3 are resistant in many models of tissue fibrosis [10]. In particular, Smad3 deficient 
mice are protected from albuminuria and renal fibrosis in type 1 DN [11], and are resistance 
to high fat diet (HFD) induced obesity, insulin resistance and diabetes [12, 13]. In addition, 
Smad3 deficiency protects mice from HFD-induced kidney disease [14]. By contrast, little is 
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known about Smad4 in diabetes or DN. Blockade of Smad4 in pancreatic beta cells 
attenuated HFD-induced glucose intolerance, but not insulin resistance [15], while Smad4 
protein levels in skeletal muscle are up-regulated in the obese subjects compared to the lean 
subjects [16]. Of note, activation of AMP-activated protein kinase (AMPK) inhibits nuclear 
translocation of Smad4, reduces mesangial matrix accumulation and early DN [17]. In 
addition, studies in colon cancer cells show that Smad4 deficiency increases aerobic 
glycolysis and enhances cell migration [18]. Taken together, these lines of evidence suggest 
that Smad4 may play a distinct role in metabolism which could be relevant to obesity and 
type 2 diabetes. Therefore, the aim of the current study was to determine whether Smad4 
plays a pathologic role in type 2 DN.   
We investigated Smad4 function in kidney disease in a well validated mouse model of 
accelerated type 2 diabetes which employs HFD and a single low dose streptozotocin (STZ) 
injection [19-28]. The HFD/STZ model was performed in hypertensive eNOS deficient mice 
which have increased susceptibility to diabetic kidney disease [29-31]. Knock-down of 
Smad4 expression in the kidney halted the progression of DN. Furthermore, conditional 
Smad4 deletion in podocytes was sufficient to protect against DN, without affecting obesity. 
Under diabetic conditions, Smad4 was present in podocyte mitochondria in association with 
reduced glycolysis and oxidative phosphorylation (OXPHOS), and increased production of 
reactive oxygen species. We show that Smad4 interacts directly with the rate-limiting 
glycolytic enzyme PKM2 and with ATPase Inhibitory Factor 1 (ATPIF1) to regulate 
glycolysis and OXPHOS in podocytes, respectively. In summary, our study uncovers both a 
pathologic role and a novel mechanism of action by which Smad4 in podocytes promotes 
kidney disease in type 2 diabetes. 
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Results 
Knock-down of Smad4 in the kidney improves renal function and halts progression of 
type 2 DN 
To investigate the role of Smad4 in the progression of type 2 DN, we used systemic 
administration of a Locked Nucleic Acid (LNA) to knock-down Smad4 mRNA and protein 
expression in the kidney. LNA are nucleic acid analogues in which the ribose ring is “locked” 
by a methylene bridge [32,33], resulting in increased target specificity and resistance to both 
exonucleases and endonucleases, giving excellent stability in vivo[34-36]. In particular, LNA 
anti-sense oligonucleotides exhibit preferential uptake by the kidney[37, 38]. 
 
First, we validated efficient Smad4 knock-down in cultured podocytes 4 days after the 
addition of Smad4 LNA, while control LNA did not affect Smad4 expression (Fig. 1A). Next, 
we sought to knock-down Smad4 in type 2 diabetes with established kidney disease. In this 
model, hypertensive eNOS-/- mice on the C57BL/6J background are placed on a high fat diet 
(HFD) for 30 weeks with a single STZ injection on week 8 to further increase blood glucose 
levels to diabetic state while remaining hyperinsulinaemia, a characteristic of type 2 diabetes 
[19-31]. This regimen results in hyperglycaemia, hyperinsulinaemia, albuminuria, 
glomerulosclerosis and reduced kidney function (Suppl. Fig 1). Groups of 8 mice were 
treated with 10mg/kg Smad4 LNA or control LNA (CTL LNA) by once weekly 
intraperitoneal injection from week 24 until being killed at week 30 (Fig. 1B). Smad4 LNA 
efficiently down-regulated Smad4 protein levels in the kidney, without affecting protein 
levels of Smad3 or the glycolysis enzyme, PKM2 (Fig. 1C&D). In addition, we demonstrated 
efficient knock-down of Smad4 in podocytes isolated from these mice (Fig. 1E). By contrast, 
Smad4 expression in liver, lung and spleen was unaffected by Smad4 LNA treatment (Fig 
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1F-H). Body weight, glucose intolerance and hyperglycemia were equivalent in the LNA 
treated groups as shown by HbA1c levels (Fig. 1I & Suppl. Fig 2). CTL LNA treated mice 
exhibited substantial podocyte damage at week 30 as shown by a reduction in the number of 
podocytes (defined by p57 immunostaining) and by a reduction in the area of staining for the 
podocyte marker, synaptopodin (Fig 1J&K and Suppl. Fig 3A-C). Smad4 LNA treatment 
also significantly reduced the severity of glomerulosclerosis compared to CTL LNA 
treatment as illustrated by PAS staining and quantified using collagen IV deposition (Fig. 1L-
O and Suppl. Fig 3D-F). In addition, Smad4 LNA treatment significantly reduced 
albuminuria (urine albumin to creatinine ratio) and improved renal function (serum cystatin C 
levels) in established DN compared to CTL LNA (Fig. 1P&Q). Taken together, these data 
demonstrate that administration of Smad4 LNA can selectively target Smad4 expression in 
the kidney and halt the progression of established DN, independent of the diabetic state. 
 
Upregulation of Smad4 in podocytes in type 2 DN 
The protective effects of Smad4 LNA in type 2 DN could be accounted for, at least in part, by 
protecting podocytes from injury. Therefore, we examined podocyte Smad4 expression in 
human and mouse DN. Confocal microscopy showed Smad4 staining in glomerular cells, 
including WT1+ podocytes, in normal human kidney, with relatively little co-localisation of 
Smad4 with the mitochondrial marker Tom20 (Fig 2A, C and E). Note that the WT1 
antibody used recognizes an isoform of WT1 present in the cytoplasm, not in the nucleus, of 
podocytes [39, 40]. A marked increase in Smad4 expression was evident in glomerular 
podocytes in diabetic nephropathy, with co-localisation of Smad4 and Tom20 evident in 
some cells (Fig 2B, D and F).  
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Smad4 staining is also evident in some podocytes in normal mouse kidney, with little co-
localisation of Smad4 with Tom20 (Fig 2G, I and K). However, diabetic kidneys exhibited 
up-regulation of Smad4 in glomeruli, with some Smad4 protein clearly co-localising with 
Tom20 in some glomerular cells, including podocyte-like cells (Fig 2H, J and L). Up-
regulation of Smad4 in podocytes is a relatively early event in mouse DN, with Western 
blotting of isolated podocytes showing increased Smad4 protein levels after 4 weeks of 
diabetes (Fig 2M-O). These findings suggest a potential role for Smad4 in podocyte 
metabolism.  
 
Smad4 deficiency in podocytes preserves renal function and protects mice from 
glomerulosclerosis in type 2 DN 
To specifically address the question of whether Smad4 affects podocyte function in type 2 
DN, we generated eNOS
-/-
 mice with Smad4 deletion in podocytes (eNOS
-/-
;PodCre-
Smad4
flox/flox
 mice) on the C57BL/6J background. Mice lacking Smad4 in podocytes have a 
normal phenotype. We then induced type 2 DN using the 30 week HFD/STZ model in eNOS
-
/-
;PodCre-Smad4
-/-
 and eNOS
-/-
;PodCre littermate controls. Both mouse genotypes developed 
equivalent obesity, elevated blood glucose and HbA1c levels, hyperinsulinaemia and glucose 
intolerance (Suppl Fig 4A-F). To validate conditional Smad4 deletion, podocytes were 
isolated from diabetic and non-diabetic control kidneys by flow cytometry. Western blot 
analysis confirmed efficient Smad4 deletion in podocytes from eNOS
-/-
;PodCre-Smad4
-/-
 
mice (Fig 3A). Compared to control diabetic mice, diabetic eNOS
-/-
;PodCre-Smad4
-/-
 mice 
were substantially protection against podocyte damage in terms of loss of p57+ podocytes 
and down-regulation of the podocyte specific protein, nephrin (Fig 3B-D). Control diabetic 
mice exhibited glomerular hypertrophy, mesangial matrix expansion (PAS staining), 
glomerulosclerosis (increased glomerular collagen IV deposition), reduced renal function 
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(increased serum cystatin C) and albuminuria (increased urine albumin/creatinine ratio) (Fig 
3E-I). By comparison, diabetic eNOS
-/-
;PodCre-Smad4
-/-
 mice showed marked protection 
against mesangial matrix expansion and glomerulosclerosis, although glomerular hypertrophy 
was still evident (Fig 3E-G). In addition, diabetic eNOS
-/-
;PodCre-Smad4
-/-
 mice showed 
improved renal function and reduced albuminuria (Fig 3H&I). Thus, Smad4 deficiency in 
podocytes preserved renal function and protected mice from kidney injury despite unaltered 
diabetes and obesity (Suppl Fig. 4). 
 
Smad4 deficiency in podocytes promotes glycolysis and OXPHOS activity under high 
glucose conditions 
Ozawa et al [41] demonstrated that glycolysis is a major contributor to intracellular ATP 
production in podocytes and that phosphofructokinase, a rate limiting enzyme for glycolysis, 
is expressed in podocyte foot processes. This suggests an important role for glycolysis in 
normal podocyte function, leading us to investigate whether the protective effects of Smad4 
deletion in podocytes are related to glycolysis.  
 
The Seahorse Glycolysis Stress Test demonstrated that glycolysis, glycolytic capacity, 
glycolytic reserve and non-glycolytic acidification were increased in Smad4
-/-
 compared to 
wild type podocytes under both normal (NG, 1g/L D-glucose) and high glucose (HG, 4.5g/L 
D-glucose) conditions (Fig 4A&B). The Seahorse Cell Mito Stress Test demonstrated that 
Smad4 deficiency increased basal, maximal and ATP-linked respiration, but not proton leak, 
in podocytes under both normal and high glucose conditions (Fig 4C&D), indicating that 
Smad4 deficiency increases OXPHOS activity. Electron microscopy showed that Smad4 
deficiency did not alter mitochondrial morphology (Fig 4E&F). Smad4 deficiency in cultured 
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podocytes did not alter mitochondrial copy number (Fig 4G), or change protein levels of 
three rate-limiting glycolytic enzymes or PGC-1α, the mitochondrial biogenesis marker (Fig 
4H). Compared to wild type podocytes, Smad4 deficient podocytes have a greater capacity 
for lactate production (Fig 4I&J), and have reduced reactive oxygen species (ROS) 
production under both normal and high glucose conditions (Fig 4K-M). In addition, Smad4 
deficiency prevented high glucose-induced up-regulation of NOX4 expression and down-
regulation of synaptopodin (Fig 4N). NOX4 is the main source of ROS in the kidney and 
Nox4 is increased in DN and in podocytes in response to high glucose [42-44].  Podocyte-
specific Nox4 deletion protects mice from diabetic nephropathy and this protection is 
associated with reduced renal ROS production [44]. Our studies demonstrated that Smad4 
deletion promotes glycolysis, modulates OXPHOS activity, reduces NOX4 expression and 
ROS production, and prevents high glucose-induced injury in podocytes.  
 
Smad4 modulates glycolysis in podocytes through interaction with PKM2  
Next, we investigated the mechanism by which Smad4 regulates glycolysis in podocytes. 
Protein levels of the glycolytic enzyme, PKM2, were increased in the kidney of mouse type 2 
DN compared to age-matched, non-diabetic controls (Fig 5A&B). In isolated podocytes, 
immunoprecipitation studies identified binding between Smad4 and PKM2 in non-diabetic 
cells, and this interaction was increased in podocytes from diabetic mice (Fig 5C and D). A 
time-course study showed that lactate production falls as the interaction between Smad4 and 
PKM2 increases during the culture of podocytes under high glucose conditions (Fig 5E). 
Podocytes isolated from age-matched PodCre-Smad4
-/-
 mice did not show a difference in 
PKM2 expression (Fig 4G). However, compared to wild type podocytes, cultured Smad4
-/-
 
podocytes showed increased PKM2 activity under both normal and high glucose conditions 
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(Fig 5F), suggesting that Smad4 may modulate PKM2 activity. The active form of PKM2 has 
a tetramer structure, whereas dimer and monomer forms are inactive [45]. Cross-linking 
studies showed that high glucose stimulation of podocytes caused a reduction in the active 
form of PKM2 (tetrameter), while Smad4 deficient podocytes exhibited significantly greater 
levels of the PKM2 tetramer under both normal and high glucose conditions (Fig 5G and H). 
This led us to hypothesize that Smad4 may interact with PKM2 to inhibit the formation of 
PKM2 tetramer. 
 
To further investigate the Smad4/PKM2 interaction, 293T cells were co-transfected with 
Flag-tagged PKM2 and HA-tagged Smad4 expression plasmids and cross-linking studies 
performed. Decreasing HA-Smad4 expression (upper panel) resulted in a decrease in the 
interaction between HA-Smad4 and Flag-PKM2 (middle panel) and the increase in the 
tetramer form of PKM2 and the ratio of the tetramer to dimer + monomer forms (lower panel) 
(Fig 5I). This findings provides direct evidence that Smad4 interacts with PKM2 to inhibit 
PKM2 tetramer formation.  
 
Canonical TGF-β1/Smad4 signalling involves Smad4 translocation to the nucleus to regulate 
gene transcription [4]. Indeed, mutations of the key amino acids (R100T and L43S) that 
facilitate Smad4 nuclear translocation prevent transcription of the Smad-binding element 
(SBE) [46]. If Smad4 modulation of podocyte metabolism operates via a non-canonical 
pathway, then it should be unaffected by blocking Smad4 nuclear localisation. To address 
this question, Smad4
-/-
 podocytes were transduced with retroviral vectors expressing wild 
type (Smad4
WT
) or the mutants, Smad4
R100T
 or Smad4
L43S
, which prevent Smad4 entry into 
the nucleus [46]. First, we confirmed that Smad4
R100T
 and Smad4
L43S
 expressing cells had a 
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greatly diminished response to TGF-β1 stimulation in the SBE4-luciferase assay compared to 
Smad4
WT
 cells (Fig 5J), a response that depends upon Smad4 nuclear localisation [46]. Next, 
we used immunoprecipitation to show that Smad4
R100T
/PKM2 and Smad4
L43S
/PKM2 
interactions are comparable to that of Smad4
WT
/PKM2 (Fig 5K). In addition, cells transduced 
with Smad4
R100T
 or Smad4
L43S
 were comparable to Smad4
WT
 transduced cells in terms of: 
PKM2 tetramer formation (Fig 5L), lactate and ROS production (Fig 5M&N), synaptopodin 
expression (Fig 5O) and NOX4 expression (Fig 5P). These data show that Smad4 regulation 
of glycolysis is independent of a Smad4 nuclear function. 
 
Quantitative proteomic analysis identifies downregulation of ATPIF1 in Smad4 
deficient podocytes 
Smad4 deficiency increased OXPHOS activity in podocytes, but did not alter mitochondrial 
morphology (Fig 4E&F). To investigate molecular mechanism(s) by which Smad4 regulates 
mitochondrial OXPHOS activity, we performed Mass Spectrometry (MS)-based quantitative 
proteomic analysis in mouse podocytes. First, we treated Smad4 deficient and WT mouse 
podocytes with normal or high glucose. Then, the protein was digested, labeled with TMT 
reagents and analyzed by MS for proteome quantification. We identified 5228 protein groups 
in the four experimental groups with three biological replicates. We defined significantly 
different (p<0.05 by two tailed t-test) proteins and used a criterion of 1.3-fold change or 
greater between two groups as differential protein candidates. Subsequently, the numbers of 
downregulated and upregulated proteins in the four groups were identified (Fig 6A & Suppl 
Table 1,). Bioinformatics enrichment analysis with gene ontology (GO) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) databases by the ClueGO tool [47] revealed 
that metabolic process, binding and catalytic activity are the most highly enriched pathways 
involving Smad4 (Fig 6B & Suppl. Fig 5). MS revealed that Smad4 deficiency markedly 
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reduces protein levels of ATPase Inhibitory Factor 1 (ATPIF1), the inhibitor of ATP synthase 
and the regulator of the activity of OXPHOS in mammalian tissues [48, 49], compared to WT 
podocytes under both normal and high glucose conditions (Fig 6C). MS also identified 
downregulation of Mitochondrial Pyruvate Carrier 1 (MPC1), which controls the influx of 
pyruvate into mitochondria for OXPHOS, and proteins involved in the Mitochondrial 
Respiratory Chain, such as Ndufs4, Ndufb10, Uqcrb, Cox7a21 and Cox5a (Fig 6C). The 
increase in ATP synthase activity caused by severe inhibition of ATPIF1 and the limitation of 
pyruvate influx into mitochondria attributable to downregulation of MPC1, prompted us to 
investigate whether Smad4 deficiency may increase mitochondrial OXPHOS efficiency and 
therefore decrease mitochondrial ROS production and ultimately contribute to the protection 
of Smad4 deficient podocytes from high glucose-induced injury.   
 
Smad4 binds to ATPIF1 and reduces ATPIF1 degradation 
We investigated the mechanism by which Smad4 deficiency in podocytes caused down-
regulation of ATPIF1. Western blotting confirmed a significant reduction of ATPIF1 and 
MPC1 protein levels in Smad4 deficient podocytes under both normal and high glucose 
conditions (Fig 7A). Smad4 deficiency significantly protected podocytes from high glucose-
induced loss of ATP production (Fig 7B), suggesting that Smad4 deficiency increases the 
activity of ATP synthase through down-regulation of ATPIF1.  
 
To investigate how Smad4 deletion alters ATPIF1 expression, we examined both mRNA and 
protein stability. Smad4 deficiency did not change ATPIF1 mRNA levels in mouse podocytes 
(Fig 7C). Next, we analysed whether Smad4 affects ATPIF1 mRNA half-life using 
Actinomycin-D to shut-off transcription. Similar decay curves were seen for ATPIF1 mRNA 
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in both Smad4 deficient and wild type cells (Fig 7D), suggesting that Smad4 regulates 
ATPIF1 at the posttranscriptional level. We examined ATPIF1 protein stability in mouse 
podocytes finding a very rapid accumulation of ATPIF1 protein in response to o-
phenanthroline (O-Phe), an inhibitor of mitochondrial proteases (Fig 7E) [49]. After removal 
of O-phe and addition of cycloheximide to stop de novo protein synthesis, cells were 
followed for varying periods of time. Western blot decay curves demonstrated that Smad4 
deficiency decreased the half-life of ATPIF1 protein (Fig 7E&F). Immunoprecipitation 
showed an interaction between Smad4 and ATPIF1 which was increased in podocytes 
isolated from type 2 DN compared to age-matched mouse kidneys (Fig 5C&D).  
 
To investigate whether Smad4 is required for ATPIF1 protein stability, we employed 
titratable, doxycycline (dox)-inducible sgRNA cassette/cas9 system to delete the Smad4 gene 
in a mouse podocyte cell line. Immunoprecipitation studies showed a dose-dependent knock-
down of Smad4 with increasing dox concentration. This caused a reduction in ATPIF1 
protein levels in association with a reduction in Smad4 binding to ATPIF1 (Fig 7G), 
suggesting that the interaction of Smad4 with ATPIF1 may protect ATPIF1 from degradation.  
Seahorse analysis demonstrated a dose-dependent increase in basal respiration, maximal 
respiration and ATP-linked respiration with down-regulation of Smad4 and ATPIF1 (Fig 7H-
J), suggesting that Smad4 regulates mitochondrial OXPHOS activity through ATPIF1. To 
demonstrate that this effect was independent of Smad4 nuclear localization, we used 
retroviral-mediated Smad4
WT
, Smad4
R100T
 and Smad4
L43S
 expression in Smad4 deficient 
podocytes as previously above. Immunoprecipitation studies showed that the 
Smad4
R100T
/ATPIF1 and Smad4
L43S
/ATPIF1 interactions are comparable to the 
Smad4
WT
/ATPIF1 interaction (Fig 7K). There is no significant difference in basal, maximal 
and ATP-linked respiration, proton leak, or ATP levels between podocytes expressing 
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Smad4
WT
, Smad4
R100T
 or Smad4
L43S
 (Fig 7L-N). Taken together, our data suggests that 
Smad4 may interact with ATPIF1 to modulate OXPHOS activity. The decreased expression 
level of MPC1 (Fig 7A) further suggests that Smad4 deficiency may increase OXPHOS 
efficiency through limitation of pyruvate influx into mitochondria and augmentation of 
OXPHOS activity in mouse podocytes. 
 
Discussion   
The present study demonstrates that Smad4 deficiency protects podocytes from high glucose-
induced injury through enhanced glycolysis and maintenance of mitochondrial OXPHOS, 
which consequently decreases NOX4 expression and ROS production. This is attributed to a 
non-canonical action of Smad4 in regulating glycolysis and OXPHOS via direct interactions 
with the rate-limiting glycolytic enzyme, PKM2, and with ATPIF1. Conditional Smad4 
deletion in podocytes protects against the development of DN, while Smad4 LNA halted the 
progression of established DN, identifying Smad4 as a therapeutic target in DN. 
 
Podocyte foot processes form slit diaphragms which are part of the glomerular filtration 
barrier that limits albumin filtration into the urinary space. Movement of foot processes in 
response to environmental changes requires the redistribution of actin filaments which is 
dependent upon phosphorylation-mediated signaling. This requires high levels of ATP to 
maintain normal podocyte structure and function [41, 50]. Mitochondria and glycolysis 
maintain energy homeostasis in podocytes [41, 51], with glycolysis responsible for the 
intracellular ATP distribution in the cortical area of podocytes [41]. Mitochondrial 
dysfunction with insufficient ATP production may contribute to the development of DN [52-
54]. We identified direct interactions between Smad4 and PKM2 and ATPIF1; key enzymes 
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in glycolysis and OXPHOS. These interactions were associated with reduced glycolysis and 
lactate production in podocytes under high glucose conditions, indicating that podocyte 
glycolysis is diminished in DN. The enhancement of glycolysis in Smad4 deficient podocytes 
may compensate for the loss of ATP due to mitochondrial injury, thus preventing podocyte 
damage and podocyte loss in the diabetic milieu. 
 
The mitochondrial H
+
-ATP synthase is the master of OXPHOS that catalyzes the synthesis of 
ATP using the proton gradient generated by the respiratory chain [55]. ATPIF1 is the 
biological inhibitor of the H
+
-ATP synthase [56, 57]. Overexpression of ATPIF1 leads to the 
inhibition of the ATP synthesis and the switch to an increased aerobic glycolysis in cancer 
cells [58]. By contrast, inhibition of ATPIF1 can ameliorate severe electron transport chain 
dysfunction due to reversal of the F1-F0 ATP synthase, thus maintaining mitochondrial 
membrane potential [59].  In our study, Smad4 deficiency increased pyruvate production 
through enhancement of glycolysis, but the reduction of MPC1 decreases the pyruvate influx 
into mitochondria for OXPHOS, thus reducing the ROS production. On the other hand, the 
reduced levels of ATPIF1 seen with Smad4 deletion increased activity of the H+-ATP 
synthase, resulting in the augmentation of OXPHOS efficiency and an increase in ATP 
production. Thus, Smad4 deficiency protects podocytes from high glucose-induced injury 
through this fine tuning of mitochondrial activity by positive and negative regulators.   
 
Hyperglycaemia plays an essential role in the pathogenesis of DN. Increased intracellular 
glucose results in accumulation of toxic glucose metabolites which exacerbates the 
development of DN [60, 61]. Podocyte injury and loss are early pathological changes in the 
pathogenesis of DN [62, 63]. Qi et al [64] found that enzymes in the glycolytic and 
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mitochondrial pathways are increased in individuals with long duration of diabetes but are 
protected from DN. They further demonstrated that TEPP-46, a PKM2 activator, protected 
mice against DN by increasing glucose metabolic flux, inhibiting the production of toxic 
glucose metabolites and inducing mitochondrial biogenesis to restore mitochondrial function. 
We showed that Smad4 deficiency in podocytes enhances glycolysis and lactate production, 
decreases NOX4 expression and ROS production, and protects against high glucose-induced 
injury in vitro. Importantly, mice with Smad4 deletion in podocytes exhibited significant 
protection against podocyte damage and the development of glomerulosclerosis, albuminuria 
and impaired renal function despite unaltered obesity and diabetes. These in vivo findings 
further support the hypothesis that an increase in glycolysis and lactic acid production may 
decrease intracellular free glucose and toxic glucose metabolites, thus reducing high glucose-
induced injury and providing salutary effects in DN.  
 
In canonical TGF-β/Smad signalling, Smad4 enters the nucleus as part of a complex with 
phosphorylated Smad2 and Smad3 which binds to promoter regions of target genes to 
regulate transcription [4]. However, recent studies demonstrate that Smad4 may directly 
translocate to mitochondria and interact with the mitochondrial protein cytochrome c oxidase 
II to promote apoptosis [65]. CHCHD2, a mitochondrial protein, interacts with Smad4 to 
repress TGF-β signalling in human induced pluripotent stem cells [66]. Our study 
demonstrated that Smad4 expression is increased in the podocyte cytoplasm in both human 
and mouse DN. The interactions between Smad4 and the rate-limiting glycolytic enzyme 
PKM2, and between Smad4 and ATPIF1, were increased in mice with DN. The interaction 
between Smad4 and PKM2 reduced the tetramer form of PKM2 and PKM2 activity, thus 
reducing glycolysis and lactate production under high glucose conditions in podocytes. The 
Smad4/ATPIF1 interaction protects ATPIF1 from degradation. Notably, using Smad4 R100T 
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and L43S mutations, we identified that nuclear localisation was not required for Smad4 
interactions with PKM2 and ATPIF1 in mitochondria, or for Smad4 modulation of glycolysis 
and ATP production. Thus, cytoplasmic Smad4 regulates glycolysis and OXPHOS via a 
novel, non-canonical pathway. 
  
LNA technology is currently being used in clinical trials [67]. The substantial renal 
accumulation of LNA at pharmacologically active levels makes it a feasible strategy for the 
treatment of kidney disease [37, 38]. Delivery of the Smad4 LNA reagent significantly 
decreased Smad4 expression in kidneys, but not in the liver, spleen or lung. This selective 
effect upon the kidney in experimental DN was supported by the lack of effect of Smad4 
LNA on body weight, hyperglycaemia, hyperinsulinaemia and impaired glucose tolerance. 
While the findings of Smad4 LNA treatment are consistent with the protective effects of 
Smad4 deletion in podocytes, clearly the beneficial effects of this treatment could also 
involve actions on other cell types. 
 
There are a number of limitations in these studies. The overall effects of Smad4 deletion in 
podocytes reported here may not be solely attributed to the changes observed in glycolysis 
and mitochondrial OXPHOS. It is feasible that other mechanisms such as fatty acid oxidation 
may have influenced the overall phenotype in Smad4 deficient podocytes. In addition, Smad4 
shuttles to the nucleus as a transcription factor to regulate gene transcription which could also 
have contributed to the effects seen with Smad4 deletion [46]. How signalling pathway(s) 
induce interactions between Smad4 and rate-limiting glycolytic enzymes PKM2 and ATPIF1 
were not investigated. Finally, mitochondrial measures such as citrate synthase activity were 
outside of the scope of this manuscript but certainly warrant further investigation. 
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In conclusion, these results provide new insights into the role of Smad4 in the pathogenesis of 
diabetic nephropathy. Specifically, we describe a previously unrecognised action of 
cytoplasmic Smad4 in the regulation of glycolysis and OXPHOS. These observations suggest 
that pharmacological approaches to inhibit Smad4 activity in the kidney could represent a 
therapeutic strategy for the treatment of type 2 DN. 
 
Methods 
Experimental animals and diets 
Breeding pairs of eNOS
-/-
 mice,
 
Smad4
fl/fl
 mice, tamoxifen-inducible Tg(CAG-cre/ 
Esr1)5Amc/J mice (ER-Cre), and 2.5P-Cre;Tg(NPHS2-cre)1Lbh mice were purchased from 
Jackson Laboratories (Bar Harbor, ME) and maintained at Monash Animal Services. Mice 
were fed a ND or a HFD (Specialty Feeds, Glen Forrest, WA, Australia) for 8 weeks first, 
followed by a single low dose of STZ injection (Sigma, St Louis, MO) and continued with 
HFD treatment for another 16 weeks. ND provided 1.68MJ/kg of energy from lipid (20% 
protein and 4.8% total fat). HFD provided 8.17MJ/kg of energy from lipid (22.6% protein 
and 23.5% total fat). In all experimental procedures, mice were housed in a controlled 
environment and food and water were available ad libitum. Body weights were measured 
weekly. To delete Smad4 gene, tamoxifen (20mg/kg) was given to eNOS
-/-
:ErCre-Smad4
fl/fl 
mice through intraperitoneal injection for 5 days consecutively. All experiments were 
approved by the Monash University Animal Ethics Committee and adhered to the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes. 
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Human Renal Biopsy Specimens 
Studies using human tissue were approved by the Human Ethics Committee of Monash 
Medical Centre, and written informed consent was obtained from the patients. Paraffin 
sections of renal biopsies, excess to that required for diagnosis, were examined in four cases 
of diabetic nephropathy. Normal kidney tissue was obtained from the noninvolved pole of 
nephrectomies performed as the result of renal carcinoma. 
LNA intervention study 
Smad4 LNA and CTL LNA were designed by and purchased from Exiqon, Denmark. Smad4 
LNA: 5’-TTGATGCGCGATTACT-3’; negative control LNA (CTL LNA): 5’- 
AACACGTCTATACGC-3’.  Smad4 LNA potency  was confirmed in cultured differentiated 
podocytes and 8 weeks old normal adult C57BL/6 J mice. Smad4 LNA and CTL LNA were 
dissolved in 1X PBS and directly added to cultured podocytes at final concentration of 1, 5 
and 10 μM respectively. Cultured medium were changed and Smad4 LNA or CTL LNA was 
added every day. Cells were harvested for protein analysis 4 days after the initial treatment. A 
preliminary experiment was performed to determine the effective dose range of Smad4 LNA 
in type 2 DN. A dose curve of Smad4 LNA or CTL LNA ranging from 5 to 20 mg/kg was 
administered to normal 8 weeks old C57BL/6J mice (7 groups/n = 2 mice each). Mice were 
killed after Smad4 LNA or CTL LNA administration; kidney tissues were collected to detect 
expression levels of Smad4 by Western blotting. Based on the results from this study, 
10mg/kg Smad4 LNA or CTL LNA dissolved in 1X PBS was intraperitoneally injected into 
eNOS deficient type 2 DN mice once a week for 6 weeks.  Mice were killed. Blood, urine, 
organs/tissues were collected for further analysis. No obvious side effects were observed 
during the experiments and in the organs/tissues examined. 
 
Lactate levels in cell culture supernatant 
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The concentration of lactate in podocytes, the end product of glycolysis, was determined 
using the lactate colorimetric assay kit (Abcam, Cambridge, United Kingdom). The OD was 
measured at 450 nm and the standard curve plot (nmol/well vs. OD 450 nm) was then 
generated. Finally, the lactate concentrations were determined as follows: C = La/10
6
 cells in 
a period time (mmol/l/10
6
 cells). 
 
Microalbuminuria, serum cystatin C and HbA1c  
Twenty-four-hour urine samples were collected each week after the beginning of HFD 
treatment. Microalbumin and urinary creatinine levels were measured with Albumin Mouse 
ELISA Kit (Abcam, Cambridge, MA) and Creatinine Assay Kit (Cayman Chemical, Ann 
Abor, MI), according to instructions supplied. Results are expressed as the urine 
microalbumin to creatinine ratio (μg/mg). The concentration of cystatin C in serum was 
determined using the mouse DuoSet ELISA kit (R&D Systems) according to the 
manufacturer’s instructions. The percentage of serum HbA1c level was determined by 
A1CNow
®
 (BHR Pharmaceuticals, UK) according to the manufacturer’s instructions.  
Glucose tolerance test 
For glucose tolerance test, after 6 h fasting, blood glucose was measured using a glucometer 
(Accu-chek; Roche Diagnostic Corporation, Indianapolis, IN) at 0, 15, 30, 60, and 120 min 
after an intraperitoneal injection of glucose (1 mg/g). 
Histological assessment and confocal microscopy 
A coronal slice of kidney tissue was fixed in 4% paraformal- dehyde and embedded in 
paraffin. Tissue was cut at 4 μm and stained with hematoxylin, PAS, and Masson’s trichrome. 
The degree of glomerulosclerosis and interstitial fibrosis were measured using Image J 
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software (http://rsb.info.nih.gov/ij/). The percent- age of glomerulosclerosis was calculated 
by dividing the total area of PAS positive staining in the glomerulus by the total area of the 
glomerulus. The following antibodies were used: rabbit anti-Tom20 conjugated with Alexa 
Fluor 647 (Abcam, UK), guinea-pig anti-synaptopodin antibody (Synaptic Systems, GmbH, 
Goettingen, Germany), followed by goat anti-guinea pig Alexa Fluor 488 (Invitrogen, Mount 
Waverley, VIC, Australia) and goat anti-Collagen IV (SouthernBiotech, Birmingham, AL) or 
rabbit anti-fibronectin (Sigma-Aldrich), followed by rabbit-goat Alexa Fluor 488 or goat anti-
rabbit Alexa Fluor 488 (Invitrogen). Sections were counterstained with DAPI (4, 6-
diamidino-2-phenylindole; Sigma-Aldrich, St Louis, MO) to visualize nuclei. Sections were 
analyzed with an Olympus Fluoview 1000 confocal microscope (Olympus, Tokyo, Japan), 
FV10-ASW software (version 1.3c; Olympus), and oil UPLFL × 60 objective (NA 1.25; 
Olympus). Image J (http://rsb.info.nih.gov/ij/) measured the area of staining within the 
glomerulus tuft. All scoring was performed on blinded slides. 
Immunoprecipitation and Western blotting 
Kidney tissues, cell culture samples and isolated cells from FACS were sonicated and lysed 
in 0.4 ml RIPA lysis buffer. The tissue and cell extracts were centrifuged at 3000 rpm at 4C 
for 30 minutes to remove cell debris. The protein concentrations were measured by modified 
Lowry protein assay using BSA as a protein standard (DC protein assay kit, Biorad). Cell 
lysates (1 mg) were added rabbit anti-Smad4, mouse or rabbit control IgG (Cell Signaling 
Technology) with gentle rocking overnight at 4°C then immune complex was 
immunoprecipitated using protein A/G agarose beads (Santa Cruz Biotechnology). In western 
blotting, proteins were electrophoresed through a 10% SDS-PAGE gel before transferring to 
A PVDF membrane. After blocking for 30 minutes at 4C in blocking buffer (5% skim milk 
powder in PBS with 0.1% Tween 20), the membrane was incubated over night with rabbit 
anti-synaptopodin, anti-nephrin, anti-PKM2 (Cell Signal Technology), anti-ATPIF1 (Abcam), 
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MPC-1 (Abcam) or anti-Smad4. The membrane was washed and incubated for 30 minutes at 
room temperature with a goat anti-rabbit or anti-mouse antibody conjugated with HRP (Cell 
Signal Technology). After further washing, the membrane was detected with ECL kit 
(Amersham Pharmacia Biotech, Arlington, IL, USA). α-tubulin and GAPDH were used as 
internal controls and detected by mouse anti-α-tubulin antibody conjugated with HRP and 
mouse anti-GAPDH antibody conjugated with HRP.  
Isolation of podocytes from mouse kidneys 
Kidney tissue from WT or Smad4
-/-
 mouse kidneys was digested with collagenase (Sigma). 
Single-cell suspensions were sequentially labeled with rabbit anti-nephrin (Bioss-USA, 
Woburn, MA) conjugated with Alexa Fluor 488 fluorophore. Renal nephrin+ cells were 
sorted using BD influx (BD Biosciences) [68]. A total of 8×10
5
 to 1.5 × 10
6
 cells/each type 
were harvested per kidney and analysis with qPCR, western blotting and Seahorse assay. 
 
Lentiviral CRISPR/Cas9 constructs.  
For the inducible Smad4 sgRNA constructs, the previously described FgH1tUTG plasmid 
was modified to contain the Smad4 sgRNA (Smad4 exon4 5’ 
AAACAGGTCAGCCGGCCAGTATTC3’ and 
5’ TCCCGAATACTGGCCGGCTGACCT3’) cassette, which was inserted into bi-directional 
Bsmb1 sites linked to the GFP fluorescent protein [69].  The constitutive Cas9 expression 
vectors were derived from the pFUGW, Cas9 protein linked via the T2A peptide to the 
mCherry fluorescent reporter protein [70].  
Smad4 expression retroviral vector constructs 
The plasmids encoding Flag-Smad4WT, Flag-Smad4L43S and Flag-Smad4R100T were 
obtained from the Addgene plasmid repository (Addgene Plasmid #80888. #80889 and 
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#80891 were gifts from Aristidis Moustakas) [44]. Retroviral vector plasmid encoding Flag-
Smad4WT, Flag-Smad4L43S and Flag-Smad4R100T were subcloned into pMSCV-IRES-
Puro vector.  
Virus Production and Transduction of Podocytes 
Viral particles were produced by transient transfection of 293T cells grown in 75cm culture 
flask with 10 μg of vector DNA along with the packaging constructs pLP1 (5 μg), pLP2 
(2.5 μg), and pLP/VSVG (3 μg) (Thermo Fisher) for lentivirus, or Platinum-E packaging 
cells with 10 µg of vector DNA for retrovirus, using standard calcium phosphate precipitation 
method. Virus-containing supernatants were collected at 48 hr after transfection and passed 
through a 0.45-μm filter. Virus were concentrated by precipitation using PEG-6000 [71]. For 
transduction of podocytes, cells were plated with virus and polybrene (4µg/ml), and 
incubated overnight at 33°C. Lentivirus-transduced cells were sorted using BD FACSAria™ 
III by sorting double positive (GFP+/mCherry+) cells. To induce Smad4 sgRNA expression, 
doxycycline hyclate (Sigma) was dissolved in sterile water at a stock concentration of 10 
mg/ml and added to cell culture medium for a final concentration of 1 μg/ml for 24 hours. 
Retrovirus-transduced cells were selected with 0.6 µg/ml of puromycin in culture media. 
 
Seahorse assay 
A Seahorse Bioscience XFe24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, 
MA) was used to measure oxygen consumption rates in real time from podocytes cultured in 
XFe24 FluxPak Mini cell culture microplates (Seahorse Bioscience) coated with rat tail 
collagen I (Sigma).  
Isolated mouse podocytes were seeded in XF
e
24 FluxPak Mini cell culture microplates at a 
density of 5 × 10
5
 in 300 μl of growth media and differentiated for 7 days. After incubation 
for a total of 7 days, growth medium was removed and replaced with 500μl of FAO assay 
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medium prewarmed to 37 °C, supplemented with or without Etomoxir (1μM), cultured at 
37°C anaerobic incubator. Measurements of oxygen consumption rates were performed after 
equilibration in assay medium for 0.5 to 1h. XF Cell Mito Stress Test Kit (Seahorse 
Bioscience) was used to measure oxygen consumption rates according to the instructions 
supplied. 
Conventional EM sample preparation 
Cultured cells were fixed according standard procedures in 2 % glutaraldehyde in sodium 
cacodylate buffer. Post-fixed with 1% OsO4, 1.5% K3Fe(III)(CN)6. Cells were scraped, 
pelleted and embedded in 4% ULMP-agarose. Dehydration was done with ethanol and cells 
were embedded in Epon 812. Ultrathin sections of 70nm were cut on a Leica Ultracut UCT7 
and stained with uranyl acetate and lead citrate. EM imaging was done on a Hitachi 7500 
TEM. 
Measurement of intracellular ROS accumulation 
CellROX Deep Red Reagent was from Invitrogen (Carlsbad, CA).Podocytes were treated 
with normal glucose (1g/L D-glucose) or high glucose (4.5g/L D-glucose) the indicated time 
intervals, and CellROX Deep Red Reagent was added at a final concentration of 5 μM to the 
cells and then incubated for 30 min at 37°C. Subsequently, medium was removed, and the 
cells were washed three times with PBS. The resulting fluorescence was measured using a 
fluorescence microscope (Axiovert 200M; Zeiss). 
SBE4-luciferase reporter assay 
One day after SBE4-luciferase plasmid was transfected into Smad4
-/-
 podocytes expressing 
Flag-tagged Smad4 wild type, Smad4 R100T or Smad4 L43S mutant by lipofectamine 2000. 
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Cells were treated with or without 2ng/ml TGF-β1 for 8 hours. Then cells were harvested and 
luciferase assay was performed according to the instruction in luciferase assay kit (Promega). 
RNA Extraction and Real-Time RT-qPCR 
Total RNA from cultured podocyte samples were isolated and one-step real-time RT-PCR 
and real-time qPCR performed using SYBR Green PCR Reagents (Sigma), the Thermoscript 
RT-PCR system (Invitrogen), and the Opticon DNA Engine (MJ Research Inc., South San 
Francisco, CA), according to manufacturer’s instructions. In each reaction, 0.5 μg of total 
RNA was reverse transcribed before the following PCR conditions: 94°C for 2 minutes 
followed by 40 cycles at 94°C for 15 seconds, 58°C for 30 seconds, 72°C for 30 seconds, 
with final extension at 72°C for 10 minutes. Primers used in this study were: mouse NOX4, 
fwd 5′- 'cctcctggctgcattagtct-3′, rev 5′- ctccgcacaataaaggcaca-3′; collagen IV, fwd 5′-
TGACCCTGGTGATGTTCTCA-3′, rev 5′-GCCACACCTTGTATGCCTTT; and β-actin, 
fwd 5′- agacttcgagcaggagatgg -3′, rev 5′- caatgcctgggtacatggtg -3′. Amplicon sizes were 225 
bp (NOX4) and 266bp (β-actin). The relative amount of mRNA was calculated using the 
comparative Ct (ΔCt) method compared with β-actin and expressed as the mean ± SD. 
Cross-linking to determine tetramers, dimers and monomers of PKM2 
Isolated cells by FACS or cultured cells were treated with 500-μM DSS (disuccinimidyl 
suberate; Thermo Scientific #PI21658), as per the manufacturer’s instructions, to cross-link at 
room temperature [64]. Cell number was counted. Equal numbers of cells were lysed in 4X 
Bolt LDS Sample Buffer (Invitrogen), boiled for 5 min then western blotting was performed.  
Effect of Smad4 deficiency on ATPIF1 mRNA stability 
Wild type or Smad4 deficient mouse podocytes were cultured 24 h to normalize PKM2 
mRNA expression. Thereafter, 1640 medium was changed and cells were treated with 
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actinomycin D (5 µg/ml) for 1hr and subsequently incubated with 1640 medium for further 
30, 60, 120 and 240 min. Cells were collected and RT-qPCR was performed to quantify 
ATPIF1 mRNA levels.  The following forward (F) and reverse (R) primers were used to 
amplify mouse ATPIF1 cDNA and β-actin cDNA, respectively.  ATPIF1_F: 
5’ggttcggtgtctggggtatg, mouse ATPIF1_R: 5’tcatggtgtttcctcagggc, amplicon=193bp; mouse 
β-actin_F: 5’ ccaccatgtacccaggcatt, mouse β-actin_R: 5’ actcctgcttgctgatccac, 
amplicon=177bp. 
Quantitative proteomic analysis 
The quantitative proteomic analysis was performed according to following procedures. 1. 
Protein Extraction; 2. Trypsin Digestion; 3. TMT/iTRAQ Labeling; 4. HPLC Fractionation;  
5. LC-MS/MS Analysis; 6. Database Search; and 7. Bioinformatics Methods: Gene Ontology 
(GO) annotation proteome was derived from the UniProt-GOA database (www. 
http://www.ebi.ac.uk/GOA/). Encyclopedia of Genes and Genomes (KEGG) database was 
used to annotate protein pathway. 
Statistical analysis 
Data are mean ± SD with statistical analyses performed using Student’s t-test, one way or 
two-way ANOVA from GraphPad Prism 7.0 (GraphPad Software, San Diego, CA) and 
posthoc Tukey analysis when appropriate. P<0.05 was considered statistically significant. 
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Figure legends 
Figure 1. Smad4 LNA decreases Smad4 expression and halts the progression of type 2 
diabetic nephropathy. (A) Western blotting demonstrated Smad4 expression levels in mouse 
podocytes 4 days after Smad4 LNA or CTL LNA treatment. (B) Schema illustrating 
administration of Smad4 LNA or CTL LNA in model of type II diabetic nephropathy in eNOS 
deficient mice. (C)Western blotting demonstrated expression levels of Smad4, Smad3, PKM2 
and α-Tubulin after 6-week Smad4 LNA or CTL LNA treatment in age-matched kidney or type 
2 diabetic nephropathy. (D) Western blotting demonstrated expression levels of Smad4 in WT, 
Smad4 KO (KO), control LNA-treated WT and Smad4 LNA-treated WT podocytes. (E) 
Quantification of expression levels of Smad4, Smad3, PKM2 and α-Tubulin after 6-week 
Smad4 LNA or CTL LNA treatment in age-matched kidney or type 2 diabetic nephropathy. 
Western blotting demonstrated expression levels of Smad4 and GAPDH in lung (F), spleen 
(G) and liver (H) in age-matched mice, 6-week Smad4 LNA-treated or CTL LNA-treated 
mice. (I) HbA1C after Smad4 LNA or CTL LNA treatment. (J) Quantification of p57+ cells 
per Glomerular Cross Section (GCS) in age-matched, 6-week Smad4 LNA-treated or CTL 
LNA-treated mouse kidneys. (K) Quantification of staining area of synaptopodin in glomeruli 
in age-matched, 6-week Smad4 LNA-treated or CTL LNA-treated mouse kidneys. (L-N) PAS 
staining demonstrating age-matched kidney, CTL LNA treated diabetic nephropathy and 
Smad4 LNA-treated diabetic nephropathy.  Quantification of collagen IV staining (O), 
urinary albumin/creatinine ratio (P) and; serum Cystatin C levels (Q) in age-matched mice, 
CTL LNA treated or Smad4 LNA-treated mice with type 2 diabetic nephropathy. Two-way 
ANOVA, data are mean ± s.d. from groups of eight mice. *P<0.05; ***P<0.01; 
****P<0.001; N.S, not significant, P>0.05.  
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Figure 2.  Smad4 expression is increased in human and mouse diabetic nephropathy. (A&B) 
Confocal microscopy demonstrated WT1 (green), Smad4 (red), Tom20 (green), DAPI (blue) 
and merged images in normal human kidney (A), renal biopsy with diabetic nephropathy (B). 
Digital enlargement of normal human kidney (C, E) and diabetic nephropathy (D, F). Of 
note, localization of WT1 and Smad4, and Smad4 and Tom20. Confocal microscopy 
demonstrated synaptopodin (green), Smad4 (red), Tom20 (green), DAPI (blue) and merged 
images in normal mouse kidney (G) or diabetic nephropathy (H). Digital enlargement of age-
matched mouse kidney (I, K) and diabetic nephropathy (J, L). Of note, localization of 
synaptopodin and Smad4, and Smad4 and Tom20.    (M) Nephrin (+) cells were isolated by 
FACS from mouse kidneys. Western blotting demonstrated Smad4 expression in isolated 
nephrin (+) cells (N, O).  
  
Figure 3. Smad4 deficiency in podocytes reduces kidney injury in type 2 diabetic 
nephropathy. (A) Western blotting demonstrating expression levels of Smad4, synaptopodin 
and GAPDH in nephrin (+) cells isolated from eNOS
-/-
PodCre ND, eNOS
-/-
PodCre 
HFD+STZ, eNOS
-/-
PodCre-Smad4
-/-
ND and eNOS
-/-
PodCre-Smad4
-/-
HFD+STZ treated 
mouse kidneys. (B) Quantification of p57+ cells per Glomerular Cross Section (GCS) in 
eNOS
-/-
PodCre ND, eNOS
-/-
PodCre HFD+STZ, eNOS
-/-
PodCre-Smad4
-/-
ND and eNOS
-/-
PodCre-Smad4
-/-
HFD+STZ treated mouse kidneys. (C) Western blotting demonstrating 
expression levels of nephrin and α-Tubulin in eNOS
-/-
PodCre ND, eNOS
-/-
PodCre HFD+STZ, 
eNOS
-/-
PodCre-Smad4
-/-
ND and eNOS
-/-
PodCre-Smad4
-/-
HFD+STZ treated mouse kidneys.  
(D) Quantification of ratios of nephrin/α-Tubulin in western blotting. (E) Periodic acid–
Schiff (PAS) staining of sections from ND-treated or HFD+STZ-treated eNOS
-/-
PodCre or 
eNOS
-/-
PodCre-Smad4
-/-
 mouse kidneys. (F) Confocal microscopy demonstrated collagen IV 
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expression in ND-treated or HFD+STZ-treated eNOS-/-PodCre or eNOS-/-PodCre-Smad4-/- 
mouse kidneys. Quantitation of collagen IV staining area/glomerular cross-section (G),  
serum Cystatin C levels (H) and urinary albumin/creatinine ratio (I) in ND-treated or 
HFD+STZ-treated eNOS
-/-
PodCre mouse or eNOS
-/-
PodCre-Smad4
-/-
 mouse kidneys. Data 
are mean ± s.d. from groups of eight mice. *P<0.05, **P<0.01, ***P<0.001. 
  
Figure 4. Smad4 deficiency increases glycolysis and lactate production, decreases reactive 
oxygen species and protects podocytes from high glucose-induced injury. Wild type (WT) and 
Smad4 KO mouse podocytes were treated with normal glucose (NG, 1g/L D-glucose) or high 
glucose (HG, 4.5g/L D-glucose) for 24 hrs then Seahorse was performed. Seahorse 
demonstrated real-time changes of ECAR in WT and Smad4 KO podocytes after treatment 
with glucose, oligomycin and 2-Deoxy-D-glucose (2-DG) (A). Quantification of non-
glycolytic acidification, glycolysis, glycolytic capacity and glycolytic reserve (B). Seahorse 
demonstrated real-time changes of oxygen consumption rate (OCR) after treatment with 
oligomycin, FCCP and rotenone in WT and Smad4 KO podocytes (C). Quantification of 
basal, maximal, ATP-linked respiration and reserve capacity (D).  All values are means ± SD 
of at least three independent experiments. N.S, Not Significant, P>0.05; *P< 0.05; **P< 
0.01; ***P< 0.001; ****P< 0.0001. Electron Microscopy demonstrated mitochondria 
morphology in WT (E) and Smad4 KO (F) podocytes. (G) PCR demonstrated relative 
mitochondrial copy number in WT and Smad4 KO podocytes. (H) Western blotting 
demonstrated expression of Smad4, HK1, PKM2, FPKL, PGC-1α and α-tubulin in WT and 
Smad4 KO podocytes.  Lactate production in WT or Smad4 KO podocytes under high glucose 
(HG) and normal glucose (NG) conditions (I, J). Relative fluorescence intensities of reactive 
oxygen species (ROS) under normal glucose (NG) or high glucose (HG) condition in 
podocytes (K). Relative fluorescence intensities of ROS after 24-hour NG, HG or NG+ D-
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manitol treatment in podocytes (L). Relative fluorescence intensities of ROS after 24-hour NG 
or HG treatment in WT or Smad4 KO podocytes (M). Western blotting demonstrated NOX4 
and synaptopodin expression after 24-hour NG or HG treatment in WT or Smad4 KO 
podocytes (N). All values are means ± SD of at least three independent experiments. *P < 
0.05, **P < 0.01, ***P < 0.001, ****P <.0.0001. 
  
Figure 5. Smad4 interacts with rate-limiting glycolytic enzyme PKM2 to modulate PKM2 
tetramer formation and regulate lactate production in podocytes. WB demonstrated 
expression levels of ATPIF1 and PKM2 in age-matched kidneys and 16-week type 2 diabetic 
nephropathy (A). Quantitation of arbitrary ratios of ATPIF1 and PKM2 to α-Tubulin (B). 
Immunoprecipitation (IP)/WB demonstrated the interactions between Smad4 and ATPIF1 and 
PKM2 in nephrin+ podocytes isolated from age-matched kidneys and 16-week type 2 diabetic 
nephropathy (C). Quantitation of arbitrary ratios of ATPIF1 and PKM2 to Smad4 (D). 
Lactate production in different periods of under high glucose treatment in podocytes (upper 
panel), IP/WB demonstrated interaction between Smad4 and PKM2 after 4-, 12- and 24-hour 
HG treatment in podocytes (lower panel) (E). PKM2 activities in wild type (WT), Smad4 KO 
(KO) mouse podocytes under normal glucose (NG), high glucose (HG) or D-manitol (D-M) 
treatment for 24 hours (F). Western blotting demonstrated PKM2 tetramer, dimer and 
monomer after normal glucose (NG), high glucose (HG) or D-manitol (D-M) treatment for 
24 hours in wild type (WT) or Smad4 KO (KO) mouse podocytes after cross-linking treatment 
(G). Quantification of ratios of Tetramer/Dimer+Monomer. *P<0.05; **P<0.01 (H). 293T 
cells were transduced with FlagPKM2, HASmad4 and empty vector with various dosages. 
After 48 hours, cells were collected for Western blotting (upper panel), 
Immunoprecipitation/Western blotting (middle panel) and cross-linking/Western blotting 
(lower panel). Western blotting demonstrated expression levels of HA-Smad4 (upper panel), 
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interactions of FlagPKM2 with HASmad4 (middle panel) and FlagPKM2 tetramer, dimer and 
monomer (lower panel) (I). Smad4 KO podocytes were transduced with an empty retroviral 
vector, or retroviral vectors over-expressing Smad4 WT, Smad4 R100T, or Smad4 L43S. 
SBE4-Luciferase assay demonstrated transcription activities in Smad4 KO, Smad4 WT, 
Smad4 R100T and Smad4 L43S podocytes with or without TGF-β1 treatment (J). IP/WB 
demonstrated interaction between Smad4 and PKM2 after 24-hour NG or HG treatment in 
WT, R100T and L43S podocytes (K). Cross-linking/Western blotting demonstrated PKM2 
tetramer, dimer and monomer after 24-hour NG or HG treatment in WT, R100T and L43S 
podocytes (L). Lactate production in WT, R100T, L43S and Smad4 KO podocytes after 24-
hour NG or HG treatment (M). CellRox Deep Red test demonstrated relative fluorescence 
intensity in WT, R100T, L43S and Smad4 KO podocytes treated with NG or HG for 24 hrs 
(N). WB demonstrated expression levels of Synaptopodin, Smad4 and GAPDH in WT, R100T, 
L43S and Smad4 KO podocytes treated with NG or HG for 24 hrs (O).  RT-qPCR 
demonstrated ratios of Nox4/β-actin in WT, R100T, L43S and Smad4 KO podocytes treated 
with NG or HG for 24 hrs (P). One-way ANOVA, all values are means ± SD of at least three 
independent experiments.  **P<0.01; ****P<0.0001; *P<0.05 vs WT or vs R100T or L43S 
under HG condition; ***P<0.0001 vs WT or vs R100T or L43S under NG or HG condition. 
N.S, not significant, P>0.05. 
  
Fig 6. Quantitative proteomic profiling for wild type (WT) and Smad4 knockout (KO) mouse 
podocytes under normal glucose (NG) or high glucose (HG) treatment. (A) Volcano plot of 
the protein abundance changes in response to NG or HG in WT or Smad4 KO podocytes. 
Average protein expression ratio of 3 replicates (log 2 transformed) between KO+NG vs 
WT+NG and KO+HG vs WT+HG. Different treatment groups were plotted against p-value 
by t-test (−log 10 transformed). Cutoff of p= 0.05 and 1.3-fold change were marked by blue 
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and red dots, respectively. (B) Functional annotation of altered proteome in four 
experimental groups. A GO analysis of the significantly changed proteins identified in 
proteomic analysis for biological process, molecular function, and KEGG pathway. (C) The 
figure shows protein access number, gene name, ratio and p value in four experiment groups 
in quantitative Mass Spectrometry. 
  
Figure 7. Smad4 interacts with ATPIF1 to regulate the activity of mitochondrial oxidative 
phosphorylation in mouse podocytes. (A) Western blotting (WB) demonstrated the expression 
levels of Smad4, Synaptopodin, ATPIF1, MPC1 and α-Tubulin in Smad4 deficient and wild 
type mouse podocytes under normal glucose (1g/L D-glucose, NG) or high glucose (4.5g/L 
D-glucose HG) condition. (B) Relative ATP levels in Smad4 WT, Smad4 R100T, Smad4 L43S 
or Smad4 KO podocytes treated with NG or HG for 24 hours. All values are means ± SD of at 
least three independent experiments. *P< 0.05, **P< 0.01, ***P< 0.001. N.S, P>0.05. (C) 
RT-qPCR demonstrated relative mRNA levels of ATPIF1 in WT or Smad4 KO mouse 
podocytes treated with NG or HG for 24hrs. (D) Decay curves demonstrated ATPIF1 mRNA 
half-life 30, 60, 120 and 140 mins after wild type (WT) or Smad4 knockout (KO) mouse 
podocyte were treated with 5µg/ml actinomycin D. (E) Western blotting demonstrated 
ATPIF1 expression levels in wild type or Smad4 KO mouse podocytes after treatment with 0.5 
mM o-phe for 1hr, or treatment with o-phe then removal of o-phe and treatment with 20µg/ml 
cycloheximide for different periods of time as indicated.  (F) Decay curves demonstrated 
ATPIF1 protein half-life after wild type (WT) or Smad4 knockout (KO) mouse podocyte were 
treated with 0.5 mM o-phenanthroline (o-phe) for 1 hr then o-phe was replaced with 20µg/ml 
cycloheximide for different periods of time. (G) Doxycycline (Dox) inducible sgRNA 
cassette/cas9 system to delete Smad4 gene was employed in mouse podocytes. WB and IP/WB 
demonstrated that expression of Smad4 and ATPIF1 and the interaction between Smad4 and 
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ATPIF1 decrease following Dox treatment. Seahorse demonstrated oxygen consumption rate 
(OCR) in Basal (H), Maximal (I) and ATP-linked Respiration (J) in WT or Dox-inducible 
sgRNA cassette/cas9 system in podocytes treated with different dosages of Dox. (K-N) Smad4 
KO podocytes were transduced with an empty retroviral vector, or retroviral vectors over-
expressing Smad4 WT, Smad4 R100T, or Smad4 L43S. Western blotting demonstrated 
expression levels of Smad4, ATPIF1 and β-actin (K). IP/WB demonstrated interaction 
between Smad4 and ATPIF1 in Smad4 WT, Smad4 R100T, and Smad4 L43S podocytes (K). 
Seahorse demonstrated OCR in Basal (L), Maximal (M) and ATP-linked Respiration (N) in 
Smad4 WT, Smad4 R100T, Smad4 L43S or Smad4 KO podocytes. All values are means ± SD 
of at least three independent experiments. *P< 0.05, **P< 0.01, ***P< 0.001. N.S, P>0.05. 
  
Suppl. Fig 1. (A) Schema illustrating mouse model of type II diabetic nephropathy using high 
fat diet (HFD) and a single dose streptozotocin (50mg/Kg) intraperitoneal injection. (B) 
Increment change of body weight in eNOS
+/+
 ND, eNOS
+/+
 HFD+STZ, eNOS
-/-
ND and eNOS
-
/-
 HFD+STZ. (C, D) HbA1c% (C) and plasma insulin level (D) change in eNOS
+/+
 ND, 
eNOS
+/+
 HFD+STZ, eNOS
-/-
ND and eNOS
-/-
 HFD+STZ after 24 weeks of treatment. (E) 
Periodic acid–Schiff (PAS) staining of sections from eNOS+/+ ND, eNOS+/+ HFD+STZ, 
eNOS
-/-
ND and eNOS
-/-
 HFD+STZ mouse kidneys. (F) Urinary albumin/creatinine ratio 
changes from eNOS
+/+
 ND, eNOS
+/+
 HFD+STZ, eNOS
-/-
ND and eNOS
-/-
 HFD+STZ mouse. 
(H) Serum cystatin C changes from eNOS
+/+
 ND, eNOS
+/+
 HFD+STZ, eNOS
-/-
ND and eNOS
-
/-
 HFD+STZ mouse. Data are mean ± s.d. from groups of eight mice. *P<0.05, **P<0.01, 
***P<0.001. 
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Suppl. Fig 2. Smad4 LNA administration retards the progression of mouse type 2 diabetic 
nephropathy. (A-C) changes in body weight, fasting blood glucose levels, and plasma insulin 
in age-matched, control-LNA (CTL-LNA)-treated or Smad4 LNA-treated in type 2 diabetic 
eNOS
-/-
 mice. Glucose tolerance test (E) and quantification of Glucose tolerance test (D) in 
age-matched, control-LNA (CTL-LNA)-treated or Smad4 LNA-treated in type 2 diabetic 
eNOS
-/-
 mice.  Data are mean ± s.d. from groups of 6 mice.   One way ANOVA.   
  
Suppl. Fig 3. Smad4 LNA treatment decreases podocyte injury and glomerulosclerosis in type 
2 diabetic nephropathy.  Confocal microscopy demonstrated synaptopodin (red, A-C) 
collagen IV expression (green, D-F) in age-matched kidney, CTL LNA treated diabetic 
nephropathy and Smad4 LNA-treated diabetic nephropathy.  
  
Suppl. Fig 4. Smad4 deficiency in podocytes protects mice from type 2 diabetic nephropathy. 
(A-D) changes in body weight, fasting blood glucose levels, HbA1c and plasma insulin in 
ND-treated or HFD+STZ-treated eNOS
-/-
PodCre mice or eNOS
-/-
PodCre-Smad4
-/-
 mice. 
Glucose tolerance test (E) and quantification of Glucose tolerance test (F) in ND-treated or 
HFD+STZ-treated eNOS
-/-
PodCre mice or eNOS
-/-
PodCre-Smad4
-/-
 mice. Data are mean ± 
s.d. from groups of eight mice. N.S, P>0.05; *P<0.05; **P<0.01; ***P<0.001.  
  
  
Suppl. Fig 5. Encyclopedia of Genes and Genomes (KEGG) database annotates protein 
pathways in wild type or Smad4 deficient podocytes treated with normal glucose or high 
glucose.  
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Figure 1. Smad4 LNA decreases Smad4 expression and halts the progression of type 2 diabetic 
nephropathy. (A) Western blotting demonstrated Smad4 expression levels in mouse podocytes 4 
days after Smad4 LNA or CTL LNA treatment. (B) Schema illustrating administration of Smad4 
LNA or CTL LNA in model of type II diabetic nephropathy in eNOS deficient mice. (C)Western 
blotting demonstrated expression levels of Smad4, Smad3, PKM2 and α-Tubulin after 6-week 
Smad4 LNA or CTL LNA treatment in age-matched kidney or type 2 diabetic nephropathy. (D) 
Western blotting demonstrated expression levels of Smad4 in WT, Smad4 KO (KO), control LNA-
treated WT and Smad4 LNA-treated WT podocytes. (E) Quantification of expression levels of 
Smad4, Smad3, PKM2 and α-Tubulin after 6-week Smad4 LNA or CTL LNA treatment in age-
matched kidney or type 2 diabetic nephropathy. Western blotting demonstrated expression levels 
of Smad4 and GAPDH in lung (F), spleen (G) and liver (H) in age-matched mice, 6-week Smad4 
LNA-treated or CTL LNA-treated mice. (I) HbA1C after Smad4 LNA or CTL LNA treatment. (J) 
Quantification of p57+ cells per Glomerular Cross Section (GCS) in age-matched, 6-week Smad4 
LNA-treated or CTL LNA-treated mouse kidneys. (K) Quantification of staining area of 
synaptopodin in glomeruli in age-matched, 6-week Smad4 LNA-treated or CTL LNA-treated 
mouse kidneys. (L-N) PAS staining demonstrating age-matched kidney, CTL LNA treated diabetic 
nephropathy and Smad4 LNA-treated diabetic nephropathy. Quantification of collagen IV 
staining (O), urinary albumin/creatinine ratio (P) and; serum Cystatin C levels (Q) in age-
matched mice, CTL LNA treated or Smad4 LNA-treated mice with type 2 diabetic nephropathy. 
Two-way ANOVA, data are mean ± s.d. from groups of eight mice. *P<0.05; ***P<0.01; 
****P<0.001; N.S, not significant, P>0.05.
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Figure 2.  Smad4 expression is increased in human and mouse diabetic nephropathy. (A&B) 
Confocal microscopy demonstrated WT1 (green), Smad4 (red), Tom20 (green), DAPI (blue) and 
merged images in normal human kidney (A), renal biopsy with diabetic nephropathy (B). Digital 
enlargement of normal human kidney (C, E) and diabetic nephropathy (D, F). Of note, localization 
of WT1 and Smad4, and Smad4 and Tom20. Confocal microscopy demonstrated synaptopodin
(green), Smad4 (red), Tom20 (green), DAPI (blue) and merged images in normal mouse kidney (G) 
or diabetic nephropathy (H). Digital enlargement of age-matched mouse kidney (I, K) and diabetic 
nephropathy (J, L). Of note, localization of synaptopodin and Smad4, and Smad4 and Tom20.   
(M) Nephrin (+) cells were isolated by FACS from mouse kidneys. Western blotting demonstrated 
Smad4 expression in isolated nephrin (+) cells (N, O). 
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Figure 3. Smad4 deficiency in podocytes reduces kidney injury in type 2 diabetic 
nephropathy. (A) Western blotting demonstrating expression levels of Smad4, synaptopodin
and GAPDH in nephrin (+) cells isolated from eNOS-/-PodCre ND, eNOS-/-PodCre
HFD+STZ, eNOS-/-PodCre-Smad4-/-ND and eNOS-/-PodCre-Smad4-/-HFD+STZ treated 
mouse kidneys. (B) Quantification of p57+ cells per Glomerular Cross Section (GCS) in 
eNOS-/-PodCre ND, eNOS-/-PodCre HFD+STZ, eNOS-/-PodCre-Smad4-/-ND and eNOS-/-
PodCre-Smad4-/-HFD+STZ treated mouse kidneys. (C) Western blotting demonstrating 
expression levels of nephrin and α-Tubulin in eNOS-/-PodCre ND, eNOS-/-PodCre HFD+STZ, 
eNOS-/-PodCre-Smad4-/-ND and eNOS-/-PodCre-Smad4-/-HFD+STZ treated mouse kidneys.  
(D) Quantification of ratios of nephrin/α-Tubulin in western blotting. (E) Periodic acid–Schiff 
(PAS) staining of sections from ND-treated or HFD+STZ-treated eNOS-/-PodCre or eNOS-/-
PodCre-Smad4-/- mouse kidneys. (F) Confocal microscopy demonstrated collagen IV 
expression in ND-treated or HFD+STZ-treated eNOS-/-PodCre or eNOS-/-PodCre-Smad4-/-
mouse kidneys. Quantitation of collagen IV staining area/glomerular cross-section (G),  
serum Cystatin C levels (H) and urinary albumin/creatinine ratio (I) in ND-treated or 
HFD+STZ-treated eNOS-/-PodCre mouse or eNOS-/-PodCre-Smad4-/- mouse kidneys. Data 
are mean ± s.d. from groups of eight mice. *P<0.05, **P<0.01, ***P<0.001.
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Figure 4. Smad4 deficiency increases glycolysis and lactate production, decreases reactive 
oxygen species and protects podocytes from high glucose-induced injury. Wild type (WT) and 
Smad4 KO mouse podocytes were treated with normal glucose (NG, 1g/L D-glucose) or high 
glucose (HG, 4.5g/L D-glucose) for 24 hrs then Seahorse was performed. Seahorse 
demonstrated real-time changes of ECAR in WT and Smad4 KO podocytes after treatment 
with glucose, oligomycin and 2-Deoxy-D-glucose (2-DG) (A). Quantification of non-
glycolytic acidification, glycolysis, glycolytic capacity and glycolytic reserve (B). Seahorse 
demonstrated real-time changes of oxygen consumption rate (OCR) after treatment with 
oligomycin, FCCP and rotenone in WT and Smad4 KO podocytes (C). Quantification of 
basal, maximal, ATP-linked respiration and reserve capacity (D).  All values are means ± SD 
of at least three independent experiments. N.S, Not Significant, P>0.05; *P< 0.05; **P< 
0.01; ***P< 0.001; ****P< 0.0001. Electron Microscopy demonstrated mitochondria 
morphology in WT (E) and Smad4 KO (F) podocytes. (G) PCR demonstrated relative 
mitochondrial copy number in WT and Smad4 KO podocytes. (H) Western blotting 
demonstrated expression of Smad4, HK1, PKM2, FPKL, PGC-1α and α-tubulin in WT and 
Smad4 KO podocytes.  Lactate production in WT or Smad4 KO podocytes under high glucose 
(HG) and normal glucose (NG) conditions (I, J). Relative fluorescence intensities of reactive 
oxygen species (ROS) under normal glucose (NG) or high glucose (HG) condition in 
podocytes (K). Relative fluorescence intensities of ROS after 24-hour NG, HG or NG+ D-
manitol treatment in podocytes (L). Relative fluorescence intensities of ROS after 24-hour NG 
or HG treatment in WT or Smad4 KO podocytes (M). Western blotting demonstrated NOX4 
and synaptopodin expression after 24-hour NG or HG treatment in WT or Smad4 KO 
podocytes (N). All values are means ± SD of at least three independent experiments. *P < 
0.05, **P < 0.01, ***P < 0.001, ****P <.0.0001.
Fig 5
WB
PKM2
CTL DN
α-Tubulin
A
ATPIF1
P
K
M
2
 a
ct
iv
it
ie
s 
in
 p
o
d
o
cy
te
s
WT KO
***
*
*
* *
FE
IP: PKM2
WB
PKM2
Smad4
4h         12h       24h
**
**
La
ct
at
e 
in
 p
o
d
o
cy
te
cu
lt
u
re
 s
u
p
er
n
at
an
t
(m
m
o
l/
L/
1
0
6
ce
lls
)
250 KDa
Tetramer
120 KDa
Dimer
60 KDa
Monomer
WB: α-Flag
FlagPKM2:    3     0     3     3    3 µg
HASmad4:    0     3     3    1.0 0.5µg
Empty Vector:    3    3     0     2    2.5µg
WB: α-HA
I
IP: α-Flag
WB: α-HA
H
T
e
tr
a
m
e
r/
D
im
e
r+
M
o
n
o
m
e
r
* *
**
**
G
W
B
: a
n
ti
-P
K
M
2
WT KO
N
G
H
G
D
-M N
G
H
G
D
-M
250 KDa
Tetramer
120 KDa
Dimer
60 KDa
Monomer
B
P
ro
te
in
/α
-T
u
b
u
lin
****
****
C
WB
PKM2
IP: Smad4
Smad4
CTL DN
ATPIF1
IP: IgG
C
TL D
N
Nephrin(+) podocytes D Protein/Smad4
** ****
Relative (CAGA)4-Luciferase activityJ
Smad4 KO     WT               R100T       L43S 
TGF-β1:       - +       - +        - +        - +
**** ****
****
O
WB
Syn
GAPDH
WT  R00T   L43S    KO     WT  R100T  L43S   KO
NG HG
Smad4
M
***
***
N.S
N.S
N.S
La
ct
at
e 
in
 p
o
d
o
cy
te
cu
lt
u
re
 s
u
p
er
n
at
an
t 
(m
m
o
l/
L)
N
***
N.S
N.S
N.S
R
el
at
iv
e 
Fl
u
o
re
sc
en
ce
 
In
te
n
si
ty
C
el
lR
o
x
D
ee
p
 R
ed
P
**
N.S
N.S
N.S
N
o
x4
/β
-a
ct
in
 m
R
N
A
IP: Flag
WB: 
PKM2
WB: 
Smad4
K
WT   R100T  L43S    WT   R100T  L43S  
NG HG WT   R100T  L43S    WT   R100T  L43S  
NG HG
Tetramer
Dimer
Monomer
L
Figure 5. Smad4 interacts with rate-limiting glycolytic enzyme PKM2 to modulate PKM2 tetramer 
formation and regulate lactate production in podocytes. WB demonstrated expression levels of ATPIF1 and 
PKM2 in age-matched kidneys and 16-week type 2 diabetic nephropathy (A). Quantitation of arbitrary 
ratios of ATPIF1 and PKM2 to α-Tubulin (B). Immunoprecipitation (IP)/WB demonstrated the interactions 
between Smad4 and ATPIF1 and PKM2 in nephrin+ podocytes isolated from age-matched kidneys and 16-
week type 2 diabetic nephropathy (C). Quantitation of arbitrary ratios of ATPIF1 and PKM2 to Smad4 (D). 
Lactate production in different periods of under high glucose treatment in podocytes (upper panel), IP/WB 
demonstrated interaction between Smad4 and PKM2 after 4-, 12- and 24-hour HG treatment in podocytes 
(lower panel) (E). PKM2 activities in wild type (WT), Smad4 KO (KO) mouse podocytes under normal 
glucose (NG), high glucose (HG) or D-manitol (D-M) treatment for 24 hours (F). Western blotting 
demonstrated PKM2 tetramer, dimer and monomer after normal glucose (NG), high glucose (HG) or D-
manitol (D-M) treatment for 24 hours in wild type (WT) or Smad4 KO (KO) mouse podocytes after cross-
linking treatment (G). Quantification of ratios of Tetramer/Dimer+Monomer. *P<0.05; **P<0.01 (H). 293T 
cells were transduced with FlagPKM2, HASmad4 and empty vector with various dosages. After 48 hours, 
cells were collected for Western blotting (upper panel), Immunoprecipitation/Western blotting (middle panel) 
and cross-linking/Western blotting (lower panel). Western blotting demonstrated expression levels of HA-
Smad4 (upper panel), interactions of FlagPKM2 with HASmad4 (middle panel) and FlagPKM2 tetramer, 
dimer and monomer (lower panel) (I). Smad4 KO podocytes were transduced with an empty retroviral 
vector, or retroviral vectors over-expressing Smad4 WT, Smad4 R100T, or Smad4 L43S. SBE4-Luciferase 
assay demonstrated transcription activities in Smad4 KO, Smad4 WT, Smad4 R100T and Smad4 L43S 
podocytes with or without TGF-β1 treatment (J). IP/WB demonstrated interaction between Smad4 and 
PKM2 after 24-hour NG or HG treatment in WT, R100T and L43S podocytes (K). Cross-linking/Western 
blotting demonstrated PKM2 tetramer, dimer and monomer after 24-hour NG or HG treatment in WT, R100T 
and L43S podocytes (L). Lactate production in WT, R100T, L43S and Smad4 KO podocytes after 24-hour NG 
or HG treatment (M). CellRox Deep Red test demonstrated relative fluorescence intensity in WT, R100T, 
L43S and Smad4 KO podocytes treated with NG or HG for 24 hrs (N). WB demonstrated expression levels of 
Synaptopodin, Smad4 and GAPDH in WT, R100T, L43S and Smad4 KO podocytes treated with NG or HG 
for 24 hrs (O).  RT-qPCR demonstrated ratios of Nox4/β-actin in WT, R100T, L43S and Smad4 KO 
podocytes treated with NG or HG for 24 hrs (P). One-way ANOVA, all values are means ± SD of at least 
three independent experiments.  **P<0.01; ****P<0.0001; *P<0.05 vs WT or vs R100T or L43S under HG 
condition; ***P<0.0001 vs WT or vs R100T or L43S under NG or HG condition. N.S, not significant, 
P>0.05.
ACtsz
Inmt
Cdh6
Igf2bp3
Atpif1
Abat
Ltbp2
Msln
Palm3
Fam213a
Peg10
Ces2e
Fuca2
Alb
Atpif1
Ctsz
Inmt
Ltbp2
Palm3
Msln
Fam213a
Fuca2
Ces2e
Nid2
Abat
Cdh6
GO Terms Level 1 GO Terms Level 2 KO_HGvsKO_LG KO_HGvsWT_HG KO_LGvsWT_LG WT_HGvsWT_LG Identified
Biological Process cellular process 206 1028 865 360 4739
single-organism 
process 172 869 746 269 3807
metabolic process 152 713 596 268 3424
Molecular 
Function binding 220 1060 885 396 4795
catalytic activity 115 480 417 154 2197
Cellular 
Component cell 227 1173 997 414 5444
organelle 212 1128 954 398 5102
B
C
Protein 
accession
Gene 
name KO_LG/WT_LG KO_HG/WT_HG WT_HG/WT_LG KO_HG/KO_LG
Ratio P value Ratio P value Ratio P value Ratio P value
P17710 HK1 1.132 0.146145 1.382 0.011656 1.063 0.51104 1.297 0.010324
O08528 HK2 1.167 0.178641 1.422 0.024519 0.994 0.93772 1.211 0.002585
P47857 PFKM 1.104 0.33708 0.96 0.51082 0.933 0.35664 0.811 0.106858
P52480 PKM 0.975 0.093361 0.896 0.001405 0.828 0.000104 0.761 3.65E-05
O35143 Atpif1 0.305 2.16E-05 0.194 1.63E-05 1.125 0.118417 0.717 0.004639
P63030 Mpc1 0.803 0.004744 0.699 0.004877 1.151 0.01018 1.002 0.96006
Q9CXZ1 Ndufs4 0.694 0.000136 0.678 0.000424 0.939 0.090362 0.918 0.062705
Q9DCS9 Ndufb10 0.762 0.001681 0.774 0.000182 0.952 0.021395 0.967 0.444
Q9D855 Uqcrb 0.676 0.002524 0.687 0.003916 0.89 0.030377 0.904 0.26296
Q61387 Cox7a2l 0.673 0.000323 0.678 0.002019 1.053 0.087402 1.061 0.024962
Fig. 6
Fig 6. Quantitative proteomic profiling for wild type (WT) and Smad4 knockout (KO) mouse 
podocytes under normal glucose (NG) or high glucose (HG) treatment. (A) Volcano plot of the 
protein abundance changes in response to NG or HG in WT or Smad4 KO podocytes. Average 
protein expression ratio of 3 replicates (log 2 transformed) between KO+NG vs WT+NG and 
KO+HG vs WT+HG. Different treatment groups were plotted against p-value by t-test (−log 10 
transformed). Cutoff of p= 0.05 and 1.3-fold change were marked by blue and red dots, respectively. 
(B) Functional annotation of altered proteome in four experimental groups. A GO analysis of the 
significantly changed proteins identified in proteomic analysis for biological process, molecular 
function, and KEGG pathway. (C) The figure shows protein access number, gene name, ratio and p 
value in four experiment groups in quantitative Mass Spectrometry.
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Figure 7. Smad4 interacts with ATPIF1 to regulate the activity of mitochondrial oxidative 
phosphorylation in mouse podocytes. (A) Western blotting (WB) demonstrated the expression levels of 
Smad4, Synaptopodin, ATPIF1, MPC1 and α-Tubulin in Smad4 deficient and wild type mouse podocytes 
under normal glucose (1g/L D-glucose, NG) or high glucose (4.5g/L D-glucose HG) condition. (B) Relative 
ATP levels in Smad4 WT, Smad4 R100T, Smad4 L43S or Smad4 KO podocytes treated with NG or HG for 24 
hours. All values are means ± SD of at least three independent experiments. *P< 0.05, **P< 0.01, ***P< 
0.001. N.S, P>0.05. (C) RT-qPCR demonstrated relative mRNA levels of ATPIF1 in WT or Smad4 KO mouse 
podocytes treated with NG or HG for 24hrs. (D) Decay curves demonstrated ATPIF1 mRNA half-life 30, 60, 
120 and 140 mins after wild type (WT) or Smad4 knockout (KO) mouse podocyte were treated with 5µg/ml 
actinomycin D. (E) Western blotting demonstrated ATPIF1 expression levels in wild type or Smad4 KO 
mouse podocytes after treatment with 0.5 mM o-phe for 1hr, or treatment with o-phe then removal of o-phe
and treatment with 20µg/ml cycloheximide for different periods of time as indicated.  (F) Decay curves 
demonstrated ATPIF1 protein half-life after wild type (WT) or Smad4 knockout (KO) mouse podocyte were 
treated with 0.5 mM o-phenanthroline (o-phe) for 1 hr then o-phe was replaced with 20µg/ml cycloheximide
for different periods of time. (G) Doxycycline (Dox) inducible sgRNA cassette/cas9 system to delete Smad4 
gene was employed in mouse podocytes. WB and IP/WB demonstrated that expression of Smad4 and ATPIF1 
and the interaction between Smad4 and ATPIF1 decrease following Dox treatment. Seahorse demonstrated 
oxygen consumption rate (OCR) in Basal (H), Maximal (I) and ATP-linked Respiration (J) in WT or Dox-
inducible sgRNA cassette/cas9 system in podocytes treated with different dosages of Dox. (K-N) Smad4 KO 
podocytes were transduced with an empty retroviral vector, or retroviral vectors over-expressing Smad4 WT, 
Smad4 R100T, or Smad4 L43S. Western blotting demonstrated expression levels of Smad4, ATPIF1 and β-
actin (K). IP/WB demonstrated interaction between Smad4 and ATPIF1 in Smad4 WT, Smad4 R100T, and 
Smad4 L43S podocytes (K). Seahorse demonstrated OCR in Basal (L), Maximal (M) and ATP-linked 
Respiration (N) in Smad4 WT, Smad4 R100T, Smad4 L43S or Smad4 KO podocytes. All values are means ±
SD of at least three independent experiments. *P< 0.05, **P< 0.01, ***P< 0.001. N.S, P>0.05.
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Suppl. Fig 1. (A) Schema illustrating mouse model of type II diabetic nephropathy using high fat 
diet (HFD) and a single dose streptozotocin (50mg/Kg) intraperitoneal injection. (B) Increment 
change of body weight in eNOS+/+ ND, eNOS+/+ HFD+STZ, eNOS-/-ND and eNOS-/- HFD+STZ. 
(C, D) HbA1c% (C) and plasma insulin level (D) change in eNOS+/+ ND, eNOS+/+ HFD+STZ, 
eNOS-/-ND and eNOS-/- HFD+STZ after 24 weeks of treatment. (E) Periodic acid–Schiff (PAS) 
staining of sections from eNOS+/+ ND, eNOS+/+ HFD+STZ, eNOS-/-ND and eNOS-/- HFD+STZ 
mouse kidneys. (F) Urinary albumin/creatinine ratio changes from eNOS+/+ ND, eNOS+/+
HFD+STZ, eNOS-/-ND and eNOS-/- HFD+STZ mouse. (G) Serum cystatin C changes from 
eNOS+/+ ND, eNOS+/+ HFD+STZ, eNOS-/-ND and eNOS-/- HFD+STZ mouse. Data are mean ±
s.d. from groups of eight mice. *P<0.05, **P<0.01, ***P<0.001.
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Supp Fig 2
Suppl. Fig 2. Smad4 LNA administration retards the progression of mouse type 2 diabetic 
nephropathy. (A-C) changes in body weight, fasting blood glucose levels, and plasma insulin in 
age-matched, control-LNA (CTL-LNA)-treated or Smad4 LNA-treated in type 2 diabetic eNOS-/-
mice. Glucose tolerance test (E) and quantification of Glucose tolerance test (D) in age-matched, 
control-LNA (CTL-LNA)-treated or Smad4 LNA-treated in type 2 diabetic eNOS-/- mice. Data 
are mean ± s.d. from groups of 6 mice.   One way ANOVA.  
Suppl Fig 3
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Suppl. Fig 3. Smad4 LNA treatment decreases podocyte injury and glomerulosclerosis in type 2 
diabetic nephropathy.  Confocal microscopy demonstrated synaptopodin (red, A-C) collagen IV 
expression (green, D-F) in age-matched kidney, CTL LNA treated diabetic nephropathy and 
Smad4 LNA-treated diabetic nephropathy. 
Suppl Fig 4
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Suppl. Fig 4. Smad4 deficiency in podocytes protects mice from type 2 diabetic nephropathy. (A-
D) changes in body weight, fasting blood glucose levels, HbA1c and plasma insulin in ND-
treated or HFD+STZ-treated eNOS-/-PodCre mice or eNOS-/-PodCre-Smad4-/- mice. Glucose 
tolerance test (E) and quantification of Glucose tolerance test (F) in ND-treated or HFD+STZ-
treated eNOS-/-PodCre mice or eNOS-/-PodCre-Smad4-/- mice. Data are mean ± s.d. from groups 
of eight mice. N.S, P>0.05; *P<0.05; **P<0.01; ***P<0.001. 
KEGG pathway
mmu00010 Glycolysis / Gluconeogenesis 
mmu00051 Fructose and mannose metabolism 
mmu01200 Carbon metabolism
mmu01230 Biosynthesis of amino acids 
mmu00230 Purine metabolism 
mmu04922 Glucagon signaling pathway 
mmu00030 Pentose phosphate pathway
mmu04973 Carbohydrate digestion and absorption 
mmu00520 Amino sugar and nucleotide sugar metabolism 
mmu00500 Starch and sucrose metabolism
mmu00970 Aminoacyl−tRNA biosynthesis 
mmu03010 Ribosome
mmu03050 Proteasome 
mmu04145 Phagosome
mmu04974 Protein digestion and absorption 
mmu04966 Collecting duct acid secretion 
mmu04512 ECM−receptor interaction 
mmu00531 Glycosaminoglycan degradation
mmu00260 Glycine, serine and threonine metabolism 
mmu00620 Pyruvate metabolism
mmu00190 Oxidative phosphorylation 
mmu00340 Histidine metabolism 
mmu00071 Fatty acid degradation
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Suppl Fig 5
Suppl Fig 5. Encyclopedia of Genes and Genomes (KEGG) database annotates protein pathways in 
wild type or Smad4 deficient podocytes treated with normal glucose or high glucose.
